Journal of Ophthalmology / 2019 / Article / Tab 5

Review Article

A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy

Table 5

Postoperative events and treatment in the meta-analysis.

EventsNo. of studiesCrude rate, n/NRate difference % (95% CI) for overall effectI2 for heterogeneity (%) for heterogeneity
InterventionControl

DR progression3 [1, 2, 5]12/9334/930.26 [0.13, 0.54]0.0003270.26
Maculopathy progression3 [1, 5, 6, 12]18/12868/1270.10 [0.05, 0.20]<0.0000100.81
NVG progression2 [1, 5]1/627/630.19 [0.03, 1.13]0.0700.97
Laser photocoagulation4 [1, 2, 5, 6]36/13234/1301.13 [0.59, 2.13]0.7200.86
VH1 [6]1/391/370.95 [0.06, 15.72]0.97
Elevated IOP2 [7, 9]3/870/864.12 [0.45, 37.82]0.2100.83
CH1 [7]2/230/235.47 [0.25, 120.37]0.28

IVB = intravitreal bevacizumab; DR = diabetic retinopathy; NVG = neovascular glaucoma; CI = confidence interval; VH = vitreous hemorrhage; CH = conjunctival hemorrhage.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.